Effect of music listening on hypertonia in neurologically impaired patients—systematic review

Background As music listening is able to induce self-perceived and physiological signs of relaxation, it might be an interesting tool to induce muscle relaxation in patients with hypertonia. To this date effective non-pharmacological rehabilitation strategies to treat hypertonia in neurologically impaired patients are lacking. Therefore the aim is to investigate the effectiveness of music listening on muscle activity and relaxation. Methodology The search strategy was performed by the PRISMA guidelines and registered in the PROSPERO database (no. 42019128511). Seven databases were systematically searched until March 2019. Six of the 1,684 studies met the eligibility criteria and were included in this review. Risk of bias was assessed by the PEDro scale. In total 171 patients with a variety of neurological conditions were included assessing hypertonia with both clinicall and biomechanical measures. Results The analysis showed that there was a large treatment effect of music listening on muscle performance (SMD 0.96, 95% CI [0.29–1.63], I2 = 10%, Z = 2.82, p = 0.005). Music can be used as either background music during rehabilitation (dual-task) or during rest (single-task) and musical preferences seem to play a major role in the observed treatment effect. Conclusions Although music listening is able to induce muscle relaxation, several gaps in the available literature were acknowledged. Future research is in need of an accurate and objective assessment of hypertonia.

The Effectiveness of Two Grammar Treatment Procedures for Children With SLI: A Randomized Clinical Trial

Purpose This study compared the effectiveness of two grammar treatment procedures for children with specific language impairment. Method A double-blind superiority trial with cluster randomization was used to compare a cueing procedure, designed to elicit a correct production following an initial error, to a recasting procedure, which required no further production. Thirty-one 5-year-old children with specific language impairment participated in 8 small group, classroom-based treatment sessions. Fourteen children received the cueing approach and 17 received the recasting approach. Results The cueing group made significantly more progress over the 8-week treatment period than the recasting group. There was a medium–large treatment effect in the cueing group and a negligible effect size in the recasting group. The groups did not differ in maintenance of treatment effects 8 weeks after treatment. In single-subject analyses, 50% of children in the cueing group and 12% in the recasting group showed a significant treatment effect. Half of these children maintained the treatment effect 8 weeks later. Conclusion Treatment that used a structured cueing hierarchy designed to elicit a correct production following a child's error resulted in significantly greater improvement in expressive grammar than treatment that provided a recast following an error.

Low-dose Infliximab (3 mg/kg) Significantly Reduces Spinal Inflammation on Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis: A Randomized Placebo-controlled Study

Objective.To evaluate the influence of low-dose infliximab (IFX) on spinal inflammation scored by magnetic resonance imaging (MRI). The dose recommended for rheumatoid arthritis (3 mg/kg) is also clinically effective for ankylosing spondylitis (AS), although effects on spinal inflammation as defined by MRI have yet to be described in a placebo-controlled trial.Methods.In a 12-week double-blind period, patients were randomized 1:1 to receive either IFX 3 mg/kg at 0, 2, and 6 weeks, or placebo. Spinal inflammation in discovertebral units (DVU) was measured by the Spondyloarthritis Research Consortium of Canada (SPARCC) MRI Index at baseline and 12 weeks by 3 readers blinded to timepoint and treatment allocation. We also compared reliability and discrimination of the SPARCC MRI index based on evaluation of the entire spine (23 DVU score) compared to assessment of only the 6 most severely affected DVU (6 DVU score).Results.At Week 12, patients treated with IFX experienced mean reductions of 55.1% and 57.2% in the 6 DVU and 23 DVU SPARCC scores, respectively, compared with a mean increase of 5.8% and decrease of 3.4% in 6 DVU and 23 DVU scores, respectively, for patients taking placebo (p < 0.001). A large treatment effect (Guyatt’s effect size ≥ 1.7) and high reliability was evident and comparable between 6 DVU and 23 DVU scoring methods.Conclusion.Treatment with low-dose IFX leads to a large treatment effect on spinal inflammation as measured by MRI. Scoring for inflammation of only the most severely affected regions of the spine by MRI is comparable to assessment of the entire spine.

Randomized trials in oncology stopped early for benefit: A systematic review

6513 Background: Investigators finding a large treatment effect in an interim analysis may terminate a randomized trial (RCT) earlier than planned. A systematic review (Montori et. al., JAMA 2005; 294: 2203–2209) found that RCTs stopped early for benefit are poorly reported and may overestimate the true treatment affect. The extent to which RCTs in oncology stopped early for benefit share similar concerns remains unclear. Methods: We selected RCTs in oncology which had been reported in the original systematic review and reviewed the study characteristics, features related to the decision to monitor and stop the study early (sample size, interim analyses, monitoring and stopping rules), and the number of events and the estimated treatment effects. Results: We found 29 RCTs in malignant hematology (n=6) and oncology (n=23), 52% published in 2000–2004 and 41% in 3 high-impact medical journals (New England Journal of Medicine, Lancet, JAMA). The majority (79%) of trials reported a planned sample size and, on average, recruited 67% of the planned sample size (SD 31%). RCTs reported (1) the planned sample size (n=20), (2) the interim analysis at which the study was terminated (n=16), and (3) whether the decision to stop the study prematurely was informed by a stopping rule (n=16); only 13 reported all three. There was a highly significant correlation between the number of events and the treatment effect (r=0.68, p=0.0007). The odds of finding a large treatment effect (a relative risk < median of 0.54, IQR 0.3–0.7) when studies stopped after a few events (no. events < median of 54 events, IQR 22–125) was 6.2 times greater than when studies stopped later. Conclusions: RCTs in oncology stopped early for benefit tend to report large treatment effects that may overestimate the true treatment effect, particularly when the number of events driving study termination is small. Also, information pertinent to the decision to stop early was inconsistently reported. Clinicians and policymakers should interpret such studies with caution, especially when information about the decision to stop early is not provided and few events occurred. No significant financial relationships to disclose.